| Outcome Measures: |
Primary: Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemia, during 24 weeks of treatment | Secondary: Incidence of all adverse drug reactions (ADRs), during 24 weeks of treatment|Incidence of major and minor hypoglycaemic events, in the 4 weeks preceding trial start, and at the 12 and 24 week visits|HbA1c and its change from trial start, at the 12 and 24 week visits|Fasting blood glucose (FBG) (average of the self-monitored blood glucose measurements) and its change from trial start, at the 12 and 24 week visits|FBG variability (measured as standard deviation of FBG) and its change from trial start, at the 12 and 24 weeks visits|Body weight and its change from trial start, at the 12 and 24 week visits
|
| Locations: |
Novo Nordisk Investigational Site, Mississauga, L4W 4XI, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, 100004, China|Novo Nordisk Investigational Site, Mainz, 55127, Germany|Novo Nordisk Investigational Site, Kfar Saba, 44425, Israel|Novo Nordisk Investigational Site, Rome, 00144, Italy|Novo Nordisk Investigational Site, Warszawa, PL-02-274, Poland|Novo Nordisk Investigational Site, Paco de Arcos, 2780-730, Portugal|Novo Nordisk Investigational Site, Madrid, 28033, Spain|Novo Nordisk Investigational Site, Istanbul, 34335, Turkey
|
